NCT02688712 2026-04-13
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed
NCT02178358 2022-02-25
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT04605562 2021-09-05
Umbrella Biomarker-Guided Therapy in NPC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed